Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Samuel M Moskowitz"'
Autor:
Balázs Rada, Meghan A Jendrysik, Lan Pang, Craig P Hayes, Dae-Goon Yoo, Jonathan J Park, Samuel M Moskowitz, Harry L Malech, Thomas L Leto
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e54205 (2013)
Beyond intracellular killing, a novel neutrophil-based antimicrobial mechanism has been recently discovered: entrapment and killing by neutrophil extracellular traps (NETs). NETs consist of extruded nuclear DNA webs decorated with granule proteins. A
Externí odkaz:
https://doaj.org/article/7d12465e45ee485580d439e9f83c79eb
Autor:
Robert L Young, Kenneth C Malcolm, Jennifer E Kret, Silvia M Caceres, Katie R Poch, David P Nichols, Jennifer L Taylor-Cousar, Milene T Saavedra, Scott H Randell, Michael L Vasil, Jane L Burns, Samuel M Moskowitz, Jerry A Nick
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e23637 (2011)
The inability of neutrophils to eradicate Pseudomonas aeruginosa within the cystic fibrosis (CF) airway eventually results in chronic infection by the bacteria in nearly 80 percent of patients. Phagocytic killing of P. aeruginosa by CF neutrophils is
Externí odkaz:
https://doaj.org/article/69f2fa07c93e4498adbfc3cbc386b675
Autor:
Alice Tsai, Shu-Pei Wu, Eric Haseltine, Sanjeev Kumar, Samuel M. Moskowitz, Paul Panorchan, Kushal Shah
Publikováno v:
Pulmonary Therapy, Vol 6, Iss 2, Pp 275-286 (2020)
Abstract Introduction The triple-combination (TC) cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimen elexacaftor, tezacaftor, and ivacaftor was shown to be safe and efficacious in phase 3 trials of people with cystic fibrosi
Externí odkaz:
https://doaj.org/article/381bf59ba62f4dbe8c85247fef8322ad
Autor:
Leah Cuthbertson, Alan W. Walker, Anna E. Oliver, Geraint B. Rogers, Damian W. Rivett, Thomas H. Hampton, Alix Ashare, J. Stuart Elborn, Anthony De Soyza, Mary P. Carroll, Lucas R. Hoffman, Clare Lanyon, Samuel M. Moskowitz, George A. O’Toole, Julian Parkhill, Paul J. Planet, Charlotte C. Teneback, Michael M. Tunney, Jonathan B. Zuckerman, Kenneth D. Bruce, Christopher J. van der Gast
Publikováno v:
Microbiome, Vol 8, Iss 1, Pp 1-13 (2020)
Abstract Background Chronic infection and concomitant airway inflammation is the leading cause of morbidity and mortality for people living with cystic fibrosis (CF). Although chronic infection in CF is undeniably polymicrobial, involving a lung micr
Externí odkaz:
https://doaj.org/article/9cf945cb5ee8440d8a2afcecf4936353
Autor:
Mei-Ling Han, Yan Zhu, Darren J. Creek, Yu-Wei Lin, Alina D. Gutu, Paul Hertzog, Tony Purcell, Hsin-Hui Shen, Samuel M. Moskowitz, Tony Velkov, Jian Li
Publikováno v:
mSystems, Vol 4, Iss 1 (2019)
ABSTRACT Polymyxins are a last-line therapy against multidrug-resistant Pseudomonas aeruginosa; however, resistance to polymyxins has been increasingly reported. Therefore, understanding the mechanisms of polymyxin activity and resistance is crucial
Externí odkaz:
https://doaj.org/article/3e6c577775d34b3c80ad403a98349c26
Autor:
Alice Tsai, Shu-Pei Wu, Eric Haseltine, Sanjeev Kumar, Samuel M. Moskowitz, Paul Panorchan, Kushal Shah
Publikováno v:
Pulmonary Therapy, Vol 6, Iss 2, Pp 287-287 (2020)
The original version of this article unfortunately contained a mistake.
Externí odkaz:
https://doaj.org/article/c87c1f820c7d4e369ed5c52cafec236e
Autor:
Edward F. McKone, Chenghao Chu, Claire E. Wainwright, Neil Ahluwalia, Samuel M. Moskowitz, Paul McNally, Edith T. Zemanick, Ronald L. Gibson, Jane Davies, Fengjuan Xuan, Steven M. Rowe, Tanya G. Weinstock, Bonnie W. Ramsey, Elizabeth Tullis, Susanna A McColley, David Waltz, S. Tian, Thang Ho, Jonathan H. Rayment, Sabrina Noel, Marcus A. Mall, Jennifer L. Taylor-Cousar
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 203:1522-1532
Rationale: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be efficacious and safe in patients ≥12 years of age with cystic fibrosis and at least one F508del-CFTR (cystic fibrosis trans...
Autor:
Marcus A, Mall, Rossa, Brugha, Silvia, Gartner, Julian, Legg, Alexander, Moeller, Pedro, Mondejar-Lopez, Dario, Prais, Tacjana, Pressler, Felix, Ratjen, Philippe, Reix, Paul D, Robinson, Hiran, Selvadurai, Florian, Stehling, Neil, Ahluwalia, Emilio, Arteaga-Solis, Bote G, Bruinsma, Mark, Jennings, Samuel M, Moskowitz, Sabrina, Noel, Simon, Tian, Tanya G, Weinstock, Pan, Wu, Claire E, Wainwright, Jane C, Davies
Publikováno v:
American journal of respiratory and critical care medicine. 206(11)
Autor:
Matthias Griese, Deepika Polineni, Jennifer L. Taylor-Cousar, Edward F. McKone, Samuel M. Moskowitz, Stefano Costa, Cori L. Daines, Felix C. Ringshausen, Marcus A. Mall, Nicholas J. Withers, Rachel W. Linnemann, Bradley S. Quon
Publikováno v:
American Journal of Respiratory and Critical Care Medicine
Autor:
Sivagurunathan Sutharsan, Edward F McKone, Damian G Downey, Jamie Duckers, Gordon MacGregor, Elizabeth Tullis, Eva Van Braeckel, Claire E Wainwright, Danie Watson, Neil Ahluwalia, Bote G Bruinsma, Christopher Harris, Anna P Lam, Yiyue Lou, Samuel M Moskowitz, Simon Tian, Jason Yuan, David Waltz, Marcus A Mall, Paul Aurora, Stijn Verhulst, Michael Lorenz, Jobst Roehmel, Wolfgang Gleiber, Susanne Naehrig, Florian Stehling, Silke van Koningsbruggen-Rietschel, Rainald Fischer, Damian Downey, Charles Haworth, Julian Legg, Peter Barry, Rebecca Thursfield, Simon James Doe, Tom Hilliard, Edward F Nash, Nicholas John Withers, Daniel Peckham, Helen Louise Barr, Timothy Lee, Robert Gray, Francois Vermeulen, Eef Vanderhelst, Philip J Robinson, Daniel J Smith, Siobhain A Mulrennan, Barry S Clements, Peter Wark
Publikováno v:
VX18-445-109 study group 2021, ' Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial ', The Lancet. Respiratory medicine . https://doi.org/10.1016/S2213-2600(21)00454-9
BackgroundElexacaftor plus tezacaftor plus ivacaftor is a triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimen shown to be generally safe and efficacious in people with cystic fibrosis aged 12 years or older
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75c34a7aa3d2d4d1a01b05a402f021fc
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85124502293
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85124502293